Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
Date:6/23/2009

CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ -- Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant decrease of epileptic activity in mice pre-treated with Kainic acid.

"We are pleased with these initial results that confirm the predicted efficacy of BVA-601 and encourage us to further test and develop this compound in a disease area where there is a need for new, patient-friendly therapies," said Aris Persidis, Ph.D., President of Biovista. "This successful repositioning builds on our previously reported success with BVA-101 in multiple sclerosis, expanding our CNS portfolio. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company," added Dr. Persidis.

For a non-confidential information pack on BVA-601, contact Biovista at info@biovista.com.

About Biovista's BVA-601 trial in the Kainic acid model of epilepsy

Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures may be transient signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain. Epilepsy is one of the world's oldest recognized conditions, affecting around 50 million people worldwide. Fear, discrimination and social stigma have surrounded epilepsy for centuries. Some of the stigma continues today in many countries impacting the quality of life of people with the
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Dragon Pharma Announces Results of 2009 Annual General Meeting
4. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
5. Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion
6. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
7. Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities
8. Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center
9. Shamir Optical Industry Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website
10. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
11. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... owners drew up their lists of New Year,s resolutions for 2014, ... my furry companion." Nowadays there are pet salons, dog and cat ... the little canine or feline darlings along wherever mommy or daddy ... toys at the pet store. But anyone who has ever lived ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 18 Opsona Therapeutics, a,biotechnology company focused on ... diseases, today announced the,completion of an EUR18M ($23M) ... expand both at an operational and clinical level. ... and Seroba Kernel,Life Sciences all participated in the ...
... Forschungsgemeinschaft (DFG, German Research Foundation) has announced that ... high-risk research projects. The Joint Committee of Germany,s ... approved funding for two new Reinhart Koselleck Projects. ... Professor Reinhard Drner, an atomic physicist from Frankfurt, ...
... found that tiny nanoparticles could be twice as likely ... liquids than previously believed. This opens up a ... in living cells, polymer composites, and high-tech foams, ... ways of further artificially enhancing this new found sticking ...
Cached Biology Technology:Opsona Therapeutics Closes EUR18M Funding 2Opsona Therapeutics Closes EUR18M Funding 3Opsona Therapeutics Closes EUR18M Funding 4Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects 2Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects 3Nanoparticles double their chances of getting into sticky situations 2
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
(Date:4/17/2014)... many serious conditions such as heart disease, epilepsy and ... therapies. Unfortunately, there is still much scientists do not ... and unexpected insight into the structure of sodium channels ... - which are responsible for ,fine-tuning, the activity of ... recent edition of the Journal of Biological Chemistry ...
(Date:4/17/2014)... researchers have detected new early-warning signs of the potential ... have far-reaching implications for the diagnosis and treatment of ... million Americans. , "We had not expected to see ... stages," said Ann Elsner, professor and associate dean in ... the study. "We set out to study the early ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... international consortium of 15 institutions from 12 European ... Norway, Romania, Sweden, The Netherlands, UK) has started ... The name stands for ,Biodiversity and Ecosystem Services: ... the effectiveness of arguments used for biodiversity protection ...
... the Arctic Ocean, the frozen soils within this region keep ... the Earth,s atmosphere. This sequestered carbon is more than 250 ... United States in the year 2009. As global temperatures slowly ... upon the carbon cycle when the permafrost thaws and releases ...
... metal-organic frameworks, with their nanoscopic pores and incredibly ... gas storage. But with millions of different structures ... University research team has developed a computational method ... in the discovery process. The new algorithm automatically ...
Cached Biology News:Preparing for a thaw: How Arctic microbes respond to a warming world 2Preparing for a thaw: How Arctic microbes respond to a warming world 3More promising natural gas storage? 2